NCT02411708 - Study of SANGUINATE™ In the Treatment of Sickle Cell Disease Patients With Vaso-Occlusive Crisis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

December 31, 2017

Study Completion Date

December 31, 2017

Conditions

Anemia, Sickle Cell

Interventions

DRUG

SANGUINATE

Single two-hour infusion of SANGUINATE

DRUG

Placebo

Single two-hour infusion of placebo

Trial Locations (9)

Johns Hopkins Univeristy School of Medicine, Baltimore

Virginia Commonwealth University, Richmond

FSCDR, Hollywood

Florida Health Tampa General Hospital, Tampa

Ohio State University Medical Center, Columbus

Blood Center of Wisconsin, Milwaukee

University of Maryland School of Medicine, Baltimore

Newark Beth Israel Medical Center, Newark

University of Rochester Medical Center, Rochester